


Claims

1. Compounds of formula (I)




wherein

R¹ is substituted phenyl, substituted phenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substituted phenyl-C₂₋₆-alkynyl, substituted pyridinyl, substituted pyridinyl-C₁₋₆-alkyl, substituted pyridinyl-C₂₋₆-alkenyl, substituted pyridinyl-C₂₋₆-alkynyl, substituted thiophenyl, substituted thiophenyl-C₁₋₆-alkyl, substituted thiophenyl-C₂₋₆-alkenyl or substituted thiophenyl-C₂₋₆-alkynyl, wherein substituted phenyl, substituted phenyl-C₁₋₆-alkyl, substituted phenoxy-C₁₋₆-alkyl, substituted phenyl-C₂₋₆-alkenyl, substituted phenyl-C₂₋₆-alkynyl, substituted pyridinyl, substituted pyridinyl-C₁₋₆-alkyl, substituted pyridinyl-C₂₋₆-alkenyl, substituted pyridinyl-C₂₋₆-alkynyl, substituted thiophenyl, substituted thiophenyl-C₁₋₆-alkyl, substituted thiophenyl-C₂₋₆-alkenyl and substituted thiophenyl-C₂₋₆-alkynyl are substituted by R³, R⁴ and R⁵;


Y is -OC(O)- or -C(O)-;

W is -C(O)-, -S(O)₂- or -CR⁶R⁷-;


R² is selected from the ring systems B, F, L, M, O, Z, AF, AG, AH, AJ, AN, AO, AP, AQ, AR, AS, AT, AU and AV;

**B**


,

**F**


,

**L**


,

**M**


,

**O**


,

**Z**


,

**AF**


,

**AG**


,

**AH**


,

**AJ**


,

**AN**


,

**AO**


,

**AP**


,

**AQ**


,

**AR**


,

**AS**


,

**AT**

,

**AU**

,

**AV**

;

R^3 is halogen, hydroxy, cyano, C_{1-6} -alkyl, C_{1-6} -alkoxy, C_{1-6} -alkoxy- C_{1-6} -alkyl, halo- C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{3-8} -cycloalkyl, C_{3-8} -cycloalkyl- C_{1-6} -alkyl, C_{3-8} -cycloalkyl- C_{1-6} -alkoxy, C_{3-8} -cycloalkoxy, C_{3-8} -cycloalkoxy- C_{1-6} -alkyl, C_{1-6} -alkylamino, C_{1-6} -alkylcarbonylamino, C_{3-8} -cycloalkylcarbonylamino, C_{1-6} -alkyltetrazolyl, C_{1-6} -alkyltetrazolyl- C_{1-6} -alkyl or heterocycloalkyl- C_{1-6} -alkoxy;

R^4 and R^5 are independently selected from H, halogen, hydroxy, cyano, C_{1-6} -alkyl, C_{1-6} -alkoxy, C_{1-6} -alkoxy- C_{1-6} -alkyl, halo- C_{1-6} -alkoxy, halo- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{3-8} -cycloalkyl, C_{3-8} -cycloalkyl- C_{1-6} -alkyl, C_{3-8} -cycloalkyl- C_{1-6} -alkoxy, C_{3-8} -cycloalkoxy, C_{3-8} -cycloalkoxy- C_{1-6} -alkyl, C_{1-6} -alkylcarbonylamino, C_{3-8} -cycloalkylcarbonylamino, C_{1-6} -alkyltetrazolyl, C_{1-6} -alkyltetrazolyl- C_{1-6} -alkyl or heterocycloalkyl- C_{1-6} -alkoxy;

R^6 is H or C_{1-6} -alkyl;

R^7 is H, C_{1-6} -alkyl, halogen, halo- C_{1-6} -alkyl or C_{1-6} -alkoxy;

R^9 is halogen, C_{1-6} -alkyl or C_{1-6} -alkoxy;

m, n, p and q are independently selected from 1 or 2;

r is 1, 2 or 3;

or pharmaceutically acceptable salts.

2. A compound according to claim 1, wherein

R^1 is substituted phenyl- C_{1-6} -alkyl or substituted pyridinyl, wherein substituted phenyl- C_{1-6} -alkyl and substituted pyridinyl- C_{1-6} -alkyl are substituted by R^3 , R^4 and R^5 ;

Y is a -OC(O)- or -C(O)-;

W is -C(O)-;

R^2 is selected from the ring systems O, AJ, AN and AO;

R^3 is halo- C_{1-6} -alkoxy or tetrahydropyranyl- C_{1-6} -alkoxy;

R^4 is H or C_{3-8} -cycloalkyl;

R^5 is H;

R^6 is C_{1-6} -alkyl;

R^9 is halogen, C_{1-6} -alkyl or C_{1-6} -alkoxy;

m, n, p and q are 1;

or pharmaceutically acceptable salts.

3. A compound according to claim 1 or 2, wherein R^1 is substituted phenyl- C_{1-6} -alkyl or substituted pyridinyl, wherein substituted phenyl- C_{1-6} -alkyl and substituted pyridinyl- C_{1-6} -alkyl are substituted by R^3 , R^4 and R^5 .
4. A compound according to any one of claims 1 to 4, wherein Y is -C(O)-.
5. A compound according to any one of claims 1 to 2, wherein R^2 is selected from the ring systems O, AJ, AN and AO.

6. A compound according to any one of claims 1 to 6, wherein R^2 is selected from the ring systems AJ and AO.
7. A compound according to any one of claims 1 to 7, wherein R^3 is halo- C_{1-6} -alkoxy or tetrahydropyranyl- C_{1-6} -alkoxy.
8. A compound according to any one of claims 1 to 9, wherein R^4 is H or C_{3-8} -cycloalkyl.
9. A compound according to any one of claims 1 to 11, wherein R^5 is H.
10. A compound according to any one of claims 1 to 12, wherein R^6 is C_{1-6} -alkyl.
11. A compound according to any one of claims 1 to 13, wherein R^7 is H.
12. A compound according to any one of claims 1 to 13, wherein R^9 is C_{1-6} -alkoxy.
13. A compound according to any one of claims 1 to 15, wherein m, n, p and q are 1.
14. A compound according to any one of claims 1 to 17, wherein

R^1 is substituted phenyl- C_{1-6} -alkyl or substituted pyridinyl, wherein substituted phenyl- C_{1-6} -alkyl and substituted pyridinyl- C_{1-6} -alkyl are substituted by R^3 , R^4 and R^5 ;

Y is -C(O)-;

W is -C(O)-;

R^2 is selected from the ring systems AJ and AO;

R^3 is halo- C_{1-6} -alkoxy or tetrahydropyranyl- C_{1-6} -alkoxy;

R^4 is H or C_{3-8} -cycloalkyl;

R^5 is H;

R^6 is C_{1-6} -alkyl;

R^7 is H;

R^9 is C_{1-6} -alkoxy;

m, n, p and q are 1

or pharmaceutically acceptable salts.

15. A compound according to any one of claims 1 to 20, selected from

trans-5-(1H-benzotriazole-5-carbonyl)-3a-fluoro-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

trans-5-(1H-benzotriazole-5-carbonyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

trans-1-[5-(1H-benzotriazole-5-carbonyl)-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-3-[4-(trifluoromethoxy)phenyl]propan-1-one;

trans-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-(1H-benzotriazol-5-yl)methanone;

trans-5-(1H-benzotriazole-5-carbonyl)-3a-methyl-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

trans-5-[3a-methoxy-2-[3-[4-(trifluoromethoxy)phenyl]propanoyl]-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl]-3-methyl-1H-benzimidazol-2-one;

trans-5-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrole-2-carbonyl]-3-methyl-1H-benzimidazol-2-one;

trans-[3a-methoxy-5-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridin-4-yl]methanone;

trans-1-[3a-methoxy-5-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-3-[4-(trifluoromethoxy)phenyl]propan-1-one;

trans-1-[5-(3-hydroxy-5,7-dihydro-4H-[1,2]oxazolo[5,4-c]pyridine-6-carbonyl)-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-3-[4-(trifluoromethoxy)phenyl]propan-1-one;

trans-[5-(3-hydroxy-5,7-dihydro-4H-[1,2]oxazolo[5,4-c]pyridine-6-carbonyl)-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridin-4-yl]methanone;

trans-[3a-methoxy-5-(1,4,6,7-tetrahydrotriazolo[4,5-c]pyridine-5-carbonyl)-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridin-4-yl]methanone;

trans-[5-(3-hydroxy-5,7-dihydro-4H-[1,2]oxazolo[5,4-c]pyridine-6-carbonyl)-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridin-4-yl]methanone;

(+)-trans-5-(1H-benzotriazole-5-carbonyl)-3a-methyl-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

(-)-trans-5-(1H-benzotriazole-5-carbonyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

trans-[5-(3-hydroxy-5,7-dihydro-4H-[1,2]oxazolo[5,4-c]pyridine-6-carbonyl)-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridin-4-yl]methanone;

(-)-trans-5-(1H-benzotriazole-5-carbonyl)-3a-methyl-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

(+)-trans-5-(1H-benzotriazole-5-carbonyl)-3a-methoxy-hexahydro-pyrrolo[3,4-c]pyrrole-2-carboxylic acid 4-trifluoromethoxy-benzyl ester;

and pharmaceutically acceptable salts thereof.

16. A compound according to any one of claims 1 to 21, selected from


trans-1-[5-(1H-benzotriazole-5-carbonyl)-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-3-[4-(trifluoromethoxy)phenyl]propan-1-one;

trans-[5-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridine-4-carbonyl]-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-(1H-benzotriazol-5-yl)methanone;

trans-[5-(3-hydroxy-5,7-dihydro-4H-[1,2]oxazolo[5,4-c]pyridine-6-carbonyl)-3a-methoxy-3,4,6,6a-tetrahydro-1H-pyrrolo[3,4-c]pyrrol-2-yl]-[2-cyclopropyl-6-(oxan-4-ylmethoxy)pyridin-4-yl]methanone;

and pharmaceutically acceptable salts thereof.

17. A process to prepare a compound according to any one of claims 1 to 22 comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III), wherein R^1 , R^2 , R^9 , m , n , p and q are as defined in any one of claim 1 to 22 and W is $-C(O)-$.



18. A compound according to any one of claims 1 to 22 for use as therapeutically active substance.
19. A pharmaceutical composition comprising a compound according to any one of claims 1 to 22 and a therapeutically inert carrier.
20. The use of a compound according to any one of claims 1 to 22 for the treatment or prophylaxis of ocular conditions.
21. A compound according to any one of claims 1 to 22 for the treatment or prophylaxis of ocular conditions.
22. The use of a compound according to any one of claims 1 to 22 for the preparation of a medicament for the treatment or prophylaxis of ocular conditions.
23. A method for the treatment or prophylaxis ocular conditions, which method comprises administering an effective amount of a compound according to any one of claims 1 to 22.
24. A compound according to any one of claims 1 to 22, when manufactured according to a process of claim 26.